Kent Jarvis
Foot & Ankle Surgery · Humble, TXNPI 1023467867
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Bone Support Inc. accounts for 61.5% of it on its own, with 42 other manufacturers making up the rest. Reporting peaked in 2023 at $8,222 and has fallen 60.5% since, to $3,247 in 2025.
Across 240 payments — averaging $119.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bone Support Inc.$18K
- Sanara Medtech Inc.$2K
- Stryker$2K
- Anika Therapeutics, Inc.$1K
- Trimed, Inc.$1K
- Arthrosurface Incorporated$656
- plus $4K from 37 others
What the payments were for
- Consulting fees$15,75055%
- Travel & lodging$1,8076%
- Food & beverage$11,09439%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CERAMENTBONE VOID FILLER$17,262
- CERAMENT G$6,985
- CellerateRx$1,153
- TACTOSET$655
- HemiCAP$592
- Tools - FPS$587
- HemiCAP MTP Resurfacing$561
- AUGMENT INJECTABLE$510
- Tools - AFS$504
- FORTIFY$500
- Tools - WFS$238
- PuraPly$182
- Barostim Neo System$171
- ACTISHIELD CF$122
- NuShield$119
- FFRct$115
- ENSITE$112
- NexGen$101
How this compares
$28,651 in reported general payments places this provider in the 85th percentile of 684 foot & ankle surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 151 | $1,301 |
| Pregabalin | 55 | $846 |
| Terbinafine Hcl | 39 | $837 |
| Ciclopirox | 21 | $654 |
| Gentamicin Sulfate | 12 | $431 |
| Ketoconazole | 48 | $431 |
| Mupirocin | 43 | $379 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 56 | $330 |
| Methylprednisolone | 41 | $272 |
| Cephalexin | 53 | $249 |
| Meloxicam | 77 | $238 |
| Triamcinolone Acetonide | 25 | $231 |
| Clindamycin Hcl | 19 | $216 |
| Cyclobenzaprine Hcl | 29 | $200 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 20 | $100 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Humble
- Bailey GriffinHumble$44K
- William McGarveyKaty$3.5M
- Eugene CurryDallas$3.1M
- Graham HamiltonEdinburg$2.1M
- Mark DaltonAustin$1.9M
- Kevin VarnerHouston$1.1M
- Paul KimDallas$928K
- Sherman NaglerHouston$602K
- John EarlyDallas$553K
- Michael DowneySouthlake$475K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.